Tocilizumab is an anti-interleukin-6 receptor antibody that has been shown to be effective in the treatment of systemic-onset juvenile idiopathic arthritis and rheumatoid arthritis.   A review of 392 patients with noninfectious anterior scleritis showed 1 patient with successful treatment of scleritis with Tocilizumab.  Tappeiner et al.  reported 3 patients with JIA-associated uveitis that were treated with tocilizumab. Two out of the three patients achieved inactivity of uveitis while 1 patient required increased in the osage of topical steroids. In all three patients arthritis improved. To date toclizumab has not been reported in treating NSOI. The most common side effects of tocilizumab include upper respiratory tract infections, nasopharyngitis , headache, hypertension, and transient elevation of serum liver enzyme levels.  More serious side effects include neutropenia, serious infection, and thrombocytopenia.